Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report)’s share price traded down 0.2% on Thursday . The stock traded as low as $0.12 and last traded at $0.13. 312,631 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 258,226 shares. The stock had previously closed at $0.13.
Provectus Biopharmaceuticals Price Performance
The business’s 50-day simple moving average is $0.12 and its 200-day simple moving average is $0.12.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Featured Articles
- Five stocks we like better than Provectus Biopharmaceuticals
- Stock Market Sectors: What Are They and How Many Are There?
- Micron Stock Under $100: Seize the AI-Driven Upside
- Trading Stocks: RSI and Why it’s Useful
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Business Services Stocks Investing
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
